Empagliflozin's Fuel Hypothesis: Not so Soon

Cell Metab. 2016 Aug 9;24(2):200-2. doi: 10.1016/j.cmet.2016.07.018.

Abstract

The EMPA-REG OUTCOME trial (Zinman et al., 2015) established cardioprotective effects of empagliflozin in high-risk diabetic patients, but the underlying mechanisms remain elusive. A recent hypothesis proposed that increased ketone oxidation contributed to the effect, but several caveats indicate that the role of myocardial ketone oxidation is far from clear.

Publication types

  • Comment

MeSH terms

  • Diabetes Mellitus*
  • Humans
  • Hypoglycemic Agents*
  • Myocardium

Substances

  • Hypoglycemic Agents